まとめ
軽度のインスリン誘発性低血糖症は,糖尿病患者の症状認識とアドレナリン反応を悪化させ,重度の低血糖症のリスクを増大させます. この効果は,自律神経病気がなくても存在します.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック障害 メタボリック障害
- 神経科学は神経科学である.
背景:
- インスリン誘発性低血糖症は,糖尿病管理における一般的な合併症です.
- 低血糖症の認知障害は,重要な臨床的課題です.
研究 の 目的:
- 軽度の低血糖症が症状,生理学的変化,アドレナリン反応に及ぼす影響を評価する.
- 健康な個人とインスリン依存型糖尿病患者の反応を比較する.
主な方法:
- 軽度の低血糖症 (3.2 mmol/lと2.5 mmol/l) の誘導は,10人の正常な被験者と15人の糖尿病患者で実施した.
- 血糖,反応時間,症状,生理学的パラメータ,およびプラズマアドレナリン濃度のモニタリング.
- 低血糖症状に対する意識の評価.
主要な成果:
- 3.2 mmol/lで,反応時間が長くなり,血アドレナリンの増加が正常な患者および一部の糖尿病患者で観察されました.
- 2.5 mmol/lで,糖尿病患者のうち低血糖症が認められたのは,正常値の9/10と比較して,糖尿病患者の4/15のみでした.
- 重要な生理学的反応 (症状,発汗,血圧の変化) は,主に正常で意識のある糖尿病患者で発生しました.
- アドレナリン反応は,正常および意識のある糖尿病患者で顕著であったが,反応時間はすべてのグループで長続きした.
結論:
- アドレナリン反応と症状認識の障害は,診断された自律神経疾患や主観的無意識がない場合でも,糖尿病患者では一般的です.
- 血糖値の低下を認識できない場合,糖尿病患者の重度の低血糖症のリスクが増加する可能性があります.
- これらの発見は,糖尿病のケアにおける注意深いグルコースモニタリングと管理戦略の必要性を強調しています.
関連する概念動画
The Sympathetic Nervous System
Overview
Sympathetic Activation
The sympathetic division can influence tissues and organs by releasing norepinephrine at peripheral synapses and distributing epinephrine and norepinephrine through the bloodstream. In times of crisis or stress, sympathetic activation occurs, which is regulated by sympathetic centers in the hypothalamus. As a result, sympathetic activation prepares the body for physical exertion, rapid ATP production, and heightened alertness, allowing individuals to respond effectively to challenging or...
Disorders of the Autonomic Nervous System
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...


